Developing a new vaccine platform for better COVID-19 protection
Characterization and optimization of single dose, thermostable and durable vaccine platform towards increased clinical acceptance
This study is working on a new type of vaccine called PARVAX that aims to give long-lasting protection against COVID-19 and possibly other viruses, like the flu, and they're looking for ways to make it even better and more affordable for everyone.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Schepens Eye Research Institute NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10979335 on NIH RePORTER |
What this research studies
This research focuses on creating and optimizing a novel genetic vaccine platform called PARVAX, which aims to provide durable and broad immunity against COVID-19 and potentially other pathogens. The researchers will investigate how the vaccine works and enhance its effectiveness through engineering approaches. They will also test the vaccine's ability to protect against influenza viruses in preclinical models. The goal is to develop a vaccine that is not only effective but also affordable and scalable for widespread use.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals who are at risk for COVID-19 and other respiratory infections, particularly those who may benefit from enhanced vaccine options.
Not a fit: Patients who are not at risk for COVID-19 or those who have already received effective vaccines may not receive additional benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more effective and accessible vaccine for COVID-19 and other infectious diseases.
How similar studies have performed: Other research has shown promise in developing novel vaccine platforms, indicating that this approach could lead to significant advancements in vaccine technology.
Where this research is happening
Boston, United States
- Schepens Eye Research Institute — Boston, United States (Active)
Researchers
- Principal investigator: Zabaleta, Nerea — Schepens Eye Research Institute
- Study coordinator: Zabaleta, Nerea
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.